Current challenges in pediatric heart transplantation for congenital heart disease
Open Access
- 1 October 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 20 (5) , 577-583
Abstract
Pediatric heart transplantation is an established therapy for end-stage cardiac disease without suitable medical or surgical options. However, transplantation for congenital heart disease carries an incremental risk that challenges the pediatric transplant team on multiple levels. With improved outcomes following palliative and corrective congenital cardiac surgery, cardiac transplantation has decreased in recent years as a primary therapy. Nevertheless, congenital heart disease remains the most common indication for cardiac transplantation during infancy. Primary transplantation in infancy is selectively recommended for severe systemic ventricular dysfunction, severe atrioventricular valve insufficiency, and occlusive coronary artery anomalies, particularly with single ventricle physiology. Wait-list mortality remains highest for infants with prior palliative surgery and patients with failing Fontan physiology, both of whom have limited options for effective mechanical circulatory support. The sensitized patient carries an increased risk with prolonged wait times, although virtual cross-matches and single bead assays for donor-specific antigens have facilitated the transplant process. Early and late survival after transplantation for congenital heart disease remain inferior to cardiomyopathy, with prior Fontan procedure as a major risk factor. However, among survivors at 6 months, late outcomes are generally excellent. Major late causes of death include allograft vasculopathy, post-transplant lymphoproliferative disease, and acute rejection. Noncompliance with medications remains a major risk for teenage mortality. Despite the myriad of evolving challenges, pediatric heart transplantation for congenital heart disease enjoys routine short and long-term success at experienced centers for the vast majority of such patients without other options.Keywords
This publication has 33 references indexed in Scilit:
- Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2013
- Early survival after heart transplant in young infants is lowest after failed single-ventricle palliation: A multi-institutional studyThe Journal of Heart and Lung Transplantation, 2012
- Outcomes after transplantation for “failed” Fontan: A single-institution experienceThe Journal of Thoracic and Cardiovascular Surgery, 2012
- A Risk-Prediction Model for In-Hospital Mortality After Heart Transplantation in US ChildrenAmerican Journal of Transplantation, 2012
- Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patientsThe Journal of Heart and Lung Transplantation, 2011
- Incidence and Risk Factors for Mortality in Infants Awaiting Heart Transplantation in the USAThe Journal of Heart and Lung Transplantation, 2009
- Pediatric Heart Transplantation in Human Leukocyte Antigen–Sensitized PatientsCirculation, 2007
- The prevalence of coronary arterial abnormalities in pulmonary atresia with intact ventricular septum and their influence on surgical resultsCardiology in the Young, 2007
- Outcome of Listing for Cardiac Transplantation for Failed FontanCirculation, 2006
- Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infantsThe Journal of Thoracic and Cardiovascular Surgery, 2006